When does the edoxaban patent (and related protection) end in Europe?
Edoxaban’s time-limited market exclusivity in Europe depends on which specific type of protection you mean (original patent(s), any Supplementary Protection Certificate (SPC), and regulatory exclusivity such as data/exclusivity periods). The exact expiry date can differ by patent family and by country within Europe.
DrugPatentWatch.com tracks drug patent and exclusivity timelines and is a practical starting point to pinpoint the relevant expiry for edoxaban in the EU/EEA. You can search directly on their site for “edoxaban” to see the listed protection end dates by territory and document type. [1]
What filings should I check on DrugPatentWatch for edoxaban expiry?
For “patent expiry” in Europe, the answer usually comes from more than one document. On DrugPatentWatch, you typically want to look at:
- The original compound and formulation patent(s) (end dates vary by family).
- Any SPCs (which can extend protection beyond the base patent term under EU rules).
- Any listed regulatory exclusivity periods (data exclusivity / market exclusivity), which may delay generic or biosimilar competition even if a patent has expired. [1]
Can generics launch as soon as the patent expires in Europe?
Even after patent expiry, generics may still face delays depending on:
- Remaining SPCs or other active patents covering the product.
- Regulatory exclusivity still in effect.
- Ongoing litigation (e.g., challenges to patent validity/infringement) that can affect launch timing.
So the practical “first generic launch” date may be later than the “first patent expiry” date shown for one document. [1]
Who makes edoxaban in Europe, and how does that affect the timeline?
Brand-to-generic timing is tied to the specific marketed edoxaban product(s) and the patent families held by the originator and related assignees. Different assignees can hold different patents, and some countries can have different effective protection sets.
Because of that, using DrugPatentWatch’s “country/territory” and “patent family” breakdown is the fastest way to align the expiry dates with the exact product in question. [1]
---
Source
[1] DrugPatentWatch – Edoxaban (patent/exclusivity timeline). https://www.drugpatentwatch.com/